OAM
CHRS icon

Oberweis Asset Management’s Coherus Oncology CHRS Stock Holding History

Oberweis Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-22,300
Closed -$398K – 124
2020
Q2 		$398K Sell
22,300
-13,800
-38% -$234K 0.16% 93
2020
Q1 		$586K Sell
36,100
-1,500
-4% -$27.7K 0.32% 70
2019
Q4 		$677K Buy
+37,600
New +$693K 0.23% 114

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Oberweis Asset Management's CHRS Position: Q3 2020 in Review

Oberweis Asset Management sold out of Coherus Oncology (CHRS) in Q3 2020, closing a stake of 22,300 shares — an estimated $398K sold.

Oberweis Asset Management first reported a position in CHRS in Q4 2019 and held it in 3 quarters. The position peaked at $677K in Q4 2019. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

  • Oberweis Asset Management reported no remaining Coherus Oncology position as of Q3 2020 after selling out during the quarter.
  • Oberweis Asset Management sold 22,300 Coherus Oncology shares in Q3 2020, an estimated $398K.
  • Oberweis Asset Management first reported a position in Coherus Oncology in Q4 2019 and held it in 3 quarters.
  • Oberweis Asset Management's Coherus Oncology position peaked at $677K in Q4 2019.
  • 201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on Oberweis Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.